Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd ADR (NY: RDY )

54.50 +0.04 (+0.07%)
Official Closing Price Updated: 7:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dr. Reddy's Laboratories Ltd ADR

< Previous 1 2 3 Next >
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
Why Aditxt Shares Are Surging Today
Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases. 
Via Benzinga
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development 
Via News Direct
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. 
Via Benzinga
Intercept Settles Ocaliva Litigation With Reddy's Lab
 
Via Benzinga
India Based Pharma Companies In Race To Buy Athenex, Shares Surge
 
Via Benzinga
Eton Pharma Shares Tick Higher After Offloading Hospital Products
 
Via Benzinga
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302 
Via News Direct
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. 
Via Benzinga
Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal
 
Via Benzinga
The 3 Most Undervalued Stocks in India for Your February Buy List
These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years. 
Via InvestorPlace
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
Intercept entered a deal with Amneal, likely lining up a series of new settlements. 
Via Investor's Business Daily
Journey Medical Touts Positive PK Data For Bacterial Infection Candidate
 
Via Benzinga
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. 
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Positive Phase 2 Results Of SciSparc's Cannabinoid-Based Drug Candidate May Offer Some New Hope To Tourette Syndrome Patients
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
European Cannabis Q1 2022 Quarterly Update
Just like the United States’ state-by-state movement, Europe is moving country-by-country toward providing access to cannabis. 
Via Talk Markets
Dr. Reddy's Laboratories & MediCane Health To Launch Medical Cannabis Products In Germany
Dr. Reddy's Laboratories Ltd.  (NYSE: RDY)  and MediCane Health Inc. announced the launch of its medical cannabis product in Germany. 
Via Benzinga
Flood Helping Ukraine
Emerging markets are gaining as mature markets look risky. 
Via Talk Markets
Up On Bad News
Despite the plane crash in China, Boeing's stock is up today. 
Via Talk Markets
The Ruble Is Rubble
MSCI says Russian companies are 
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the... 
Via Benzinga
Putin on the brink
For the first time in history, Swiss banks have penalized account owners for political actions and joined a SWIFT boycott. 
Via Talk Markets
Red Ink
There is little joy in stocks today as even companies reporting good results are being hit by fear of Ukraine sanctions.tbph 
Via Talk Markets
Give peace a chance
Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today. 
Via Talk Markets
NYSE-Listed Pharma Co. Dr. Reddy's To Acquire German Medical Cannabis Firm Nimbus Health GmbH
Pharmaceutical company Dr. Reddy's Laboratories Ltd. (NYSE:RDY) has entered into a definitive agreement to acquire Nimbus Health GmbH, a medical cannabis-focused licensed pharmaceutical wholesaler from... 
Via Benzinga
Weakened Tech Stocks
There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks. 
Via Talk Markets
The Last Day In January
The market is suspicious of the moves up to right matters. 
Via Talk Markets
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.